Background: McCune-Albright syndrome (MAS) typically comprises the constellation of polyostotic fibrous dysplasia, café-au-lait spots, and associated endocrinopathies including gonadotropin-independent precocious puberty, excessive growth hormone production and gigantism, hyperthyroidism, and hyperparathyroidism. Objective: We report the unique case of a boy with the diagnostic criteria of MAS accompanied by atypical short stature and macroorchidism without precocious puberty. Patient: An 8.4-year-old prepubertal boy presented with a history of recurrent bone fractures, multiple café-au-lait spots, bilateral macroorchidism, and short stature. X-ray of the extremities was consistent with polyostotic fibrous dysplasia. Serum inhibin B (IB) and anti-müllerian hormone (AMH) were elevated; testosterone, LH, and FSH were normal for age. Results: PCR-based DNA analysis of bone tissue revealed a substitution of arginine for cysteine at position 201 in the Gsα protein resulting in activation of the Gsα subunit. Conclusions: We report a second case of MAS associated with macroorchidism. In this case, isolated Sertoli cell hyperfunction was also associated with microlithiasis and was not associated with peripheral precocious puberty. Short stature not associated with GH-IGF-1 axis abnormality was a second anomalous finding in this case. Our experience suggests that the phenotypic variation in MAS is wider than previously described.

1.
Weil A: Pubertas praecox und Knochenbrüchigkeit. Case presentation of a 9-year old girl with precocious puberty, fragile bones, and dermal pigmentation. Klin Wochenschr 1922;211:4–5.
2.
McCune DJ: Osteitis fibrosa cystica: the case of a 9-year-old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Children 1936;52:743–747.
3.
Albright S, Batler AM, Hampton AO, Smith PH: Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. Report of five cases. N Engl J Med 1937;216:727–746.
4.
McCune DJ, Bruch H: Osteodystrophia fibrosa. Report of a case in which the condition was combined with precocious puberty, pathologic pigmentation of the skin and hyperthyroidism, a review of the literature. Am J Dis Child 1937;54:806–848.
5.
Weinstein L, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM: Activating mutations of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. N Engl J Med 1991;325:1688–1695.
6.
Lumbroso S, Paris F, Sultan C: Activating Gsα mutation: analysis of 113 patients with signs of McCune-Albright syndrome – a European collaborative study. The J Clin Endocrinol Metab 2004;89:2107–2113.
7.
Ringel M, Schwindinger WF, Levine MA: Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996;75:171–184.
8.
Lumbroso S, Paris F, Sultan C: McCune-Albright syndrome: molecular genetics. J Pediatr Endocrinol Metab 2002;15:875–882.
9.
Farfel Z, Bourne HR, Iiri T: The expanding spectrum of G-protein diseases. N Engl J Med 1990;340:1012–1020.
10.
Weinstein L, Yu S, Warner DR, Liu J: Endocrine manifestations of stimulatory G protein α-subunit mutations and the role of genomic imprinting. Endocr Rev 2001;22:675–705.
11.
Mauras N, Blizzard RM: The McCune-Albright syndrome. ACTA Endocrinol Suppl 1986;279:207–217.
12.
Bhansali A, Sharma BS, Sreenivasulu P, Singh P, Vashisth RK, Dash RJ: Acromegaly with fibrous dysplasia: McCune-Albright syndrome. Endocr J 2003;50:793–799.
13.
Chanson P, Dib A, Visot A, Derome PJ: McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. Eur J Endocrinol 1994;131:229–234.
14.
Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Gehron Robey P: Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. Am J Pathol 1997;151:1587–1600.
15.
Leet A, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT: Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res 2004;19:571–577.
16.
Ippolito E, Edward W, Corsi A, De Maio F, Exner UG, Robey PG; Grill F, Lala R, Massobrio M, Pinggera O, Riminucci M, Snela S, Zambakidis C, Bianco P: Natural history and treatment of fibrous dysplasia of bone: a multicenter clinicopathologic study prompted by the European Pediatric Orthopaedic Society. J Pediatr Orthop 2003;12:155–177.
17.
Ippolito E, Caterini R, Farsetti P, Potenza V: Surgical treatment of fibrous dysplasia of bone in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002;15:939–944.
18.
Chapurlat R, Hugueny P, Delmas P, Meunier P: Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004;35:235–242.
19.
Lala R, Matarazzo P, Andreo M, Bellone J, Corrias A: Bisphosphonates treatment of bone fibrous dysplasia in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2006;19:583–593.
20.
Matarazzo P, Lala R, Masi G, Andreo M, Altare F, de Sanctis C: Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002;15:929–937.
21.
Caverzasio J, Rizzoli R, Bonjour JP: Sodium-dependent phosphate transport inhibited by parathyroid hormone and cyclic AMP stimulation in an opossum kidney cell line. J Biol Chem 1986;261:3233–3237.
22.
Yamamoto T: Clinical approach to clarifying the mechanism of abnormal bone metabolism in McCune-Albright syndrome. J Bone Miner Metab 2006;24:7–10.
23.
Dent V, Gartner JM: Hypophosphataemic osteomalacia in fibrous dysplasia. Q J Med 1976;179:411–420.
24.
Yamamoto T, Miyamoto K, Ozono K, Taketani Y, Katai K, Miyauchi A, Shima M, Yoshikawa H, Yoh K, Takeda E, Okada S: Hypophosphatemic rickets accompanying McCune-Albright syndrome: evidence that a humoral factor causes hypophosphatemia. J Bone Miner Metab 2001;19:287–295.
25.
Ray R, Venara M, Coutant R, Trabut JB, Rouleau S, Lahlou N, Sultan C, Limal JM, Picard JY, Lumbroso S: Unexpected mosaicism of R201H-GNAS1 mutant bearing cells in the testes underlie macroorchidism without sexual precocity in McCune-Albright syndrome. Hum Mol Genet 2006;15:3538–3543.
26.
Cabrera M, Vogiatzi MG, New MI: Long-term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86:3070–3078.
27.
Ganem J, Workman K, Shaban S: Testicular microlithiasis is associated with testicular pathology. Urology 1999;53:209–213.
28.
Dagash H, Mackinnon EA: Testicular microlithiasis: what does it mean clinically? Br J Urol 2006;99:157–160.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.